Patents Expiring in December 2038
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ||||
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY | ||||
| Fennec Pharms Inc | PEDMARK | sodium thiosulfate | SOLUTION;INTRAVENOUS | 212937-001 | Sep 20, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF REDUCING OTOTOXICITY IN A HUMAN PEDIATRIC PATIENT ABOUT 5 YEARS OF AGE OR UNDER WITH LOCALIZED MEDULLOBLASTOMA COMPRISING ADMINISTERING SODIUM THIOSULFATE ABOUT SIX HOURS AFTER ADMINISTRATION OF CISPLATIN | |||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ||||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | |||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ||||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
